As SIRT1 is a NAD+-dependent histone deacetylase, NAD+ supplement by providing its precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) has been proved to be beneficial in treating CVDs and metabolic diseases in animal models (Bonkowski and Sinclair, 2016; Hershberger et al., 2017; Kane and Sinclair, 2018). The gene discussed is SIRT1; the disease is metabolic disease.